Patents Assigned to Merck
  • EFFECT PIGMENTS
    Publication number: 20240199886
    Abstract: Opaque fluoride-doped effect pigments having a metallic lustre based on flake-form substrates, and a process for the preparation of these pigments, and the use thereof, in particular in automotive paints and cosmetic formulations.
    Type: Application
    Filed: December 18, 2023
    Publication date: June 20, 2024
    Applicant: Merck Patent GmbH
    Inventors: Johann Bauer, Andrea Heyland
  • ROTAVIRUS VECTORS FOR HETEROLOGOUS GENE DELIVERY
    Publication number: 20240200099
    Abstract: Rotavirus vectors encoding in their genome a heterologous gene, and nucleic acid constructs encoding such rotavirus vectors. The rotavirus vector genome may include a rotavirus non-structural protein, a 2A peptide downstream of the rotavirus non-structural protein, and a heterologous protein downstream of the 2A peptide. The heterologous gene may be, for example, a SARS-CoV-2 spike protein or a fragment thereof, or an RSV F protein or a fragment thereof.
    Type: Application
    Filed: April 11, 2022
    Publication date: June 20, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Dai Wang, Jiajie Wei
  • AROMATIC ISOTHIOCYANATES
    Publication number: 20240199957
    Abstract: The present invention relates to a compound of formula GF in which the occurring groups and parameters have the meanings defined in claim 1, to a liquid crystal medium comprising a compound of formula GF and to high-frequency components comprising these media, especially microwave components for high-frequency devices, such as devices for shifting the phase of microwaves, tunable filters, tunable metamaterial structures, and electronic beam steering antennas, e.g. phased array antennas.
    Type: Application
    Filed: March 29, 2022
    Publication date: June 20, 2024
    Applicant: MERCK PATENT GMBH
    Inventors: Constanze BROCKE, Dagmar KLASS, Carsten FRITZSCH
  • SYNTHESIS OF FLUORINATED CYCLIC DINUCLEOTIDES
    Publication number: 20240199680
    Abstract: The present invention relates to efficient processes useful in the preparation of fluorinated cyclic dinucleosides, such as [P(R)]-2?-deoxy-2?-fluoro-5?-O—[(R)-hydroxymercaptophosphinyl]-P-thio-?-D-arabino-adenylyl-(3??5?)-3?-deoxy-3?-fluoroguanosine cyclic nucleotide, which is also known as (2R,5R,7R,8S,10R,12aR,14R,15S,15aR,16R)-7-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-14-(6-amino-9H-purin-9-yl)-15,16-difluoro-2, 10-bis(sulfanyl)octahydro-2H,10H, 12H-2?5,10?5-5,8-methanofuro[3,2-1][1, 3,6,9,11,2,10]pentaoxadiphosphacyclotetradecine-2,10-dione. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.
    Type: Application
    Filed: March 28, 2022
    Publication date: June 20, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Chihui An, Patrick S. Fier, Kaori Hiraga, Zhijian Liu, Nicholas M. Marshall, John McIntosh, Steven P. Miller, Jeffrey C. Moore, Grant S. Murphy, Jennifer V. Obligacion, Weilan Pan, Feng Peng, Nastaran Salehi Marzijarani, Matthew S. Winston
  • Cyclic polypeptides for PCSK9 inhibition
    Patent number: 12012468
    Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
    Type: Grant
    Filed: September 27, 2022
    Date of Patent: June 18, 2024
    Assignees: MERCK SHARP & DOHME LLC, RA PHARMACEUTICALS, INC.
    Inventors: Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Mark W. Embrey, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. Gilbert, Aurash Shahripour, Yusheng Xiong
  • PROCESS FOR CONTINUOUS HOT MELT GRANULATION OF LOW SOLUBLE PHARMACEUTICALS
    Publication number: 20240189239
    Abstract: The present invention relates to a process for loading a polymer with an active pharmaceutical ingredient in a melt granulation process and to the prepared product. More specifically the invention relates to a process of preparing granules which contain at least one active pharmaceutical ingredient and polyvinyl alcohol.
    Type: Application
    Filed: March 31, 2022
    Publication date: June 13, 2024
    Applicant: Merck Patent GmbH
    Inventors: Thomas KIPPING, Finn BAUER, Nicole DI GALLO, Anja-Nadine KNUETTEL, Alessandro Giuseppe ELIA
  • PLASMA KALLIKREIN INHIBITORS
    Publication number: 20240190892
    Abstract: The present invention provides a compound of formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
    Type: Application
    Filed: March 16, 2022
    Publication date: June 13, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Natalija Cernaka, Anthony K. Ogawa, Alan C. Cheng, Jianming Bao, Phillip Patrick Sharp, Jovan Alexander Lopez, Dong Xiao, Haiqun Tang
  • Identifying biosynthetic gene clusters
    Patent number: 12009060
    Abstract: A BGC prediction system identifies candidate biosynthetic gene clusters (BGCs) within genomes using machine-learned models, such as a shallow neural network and recurrent neural network (RNN). A set of domains within a genome sequence are identified, each domain corresponds to a set of domain identifiers. A shallow neural network block is applied to each set of domain identifiers to produce a set of vectors. An RNN block is applied to the set of vectors to produce a BGC class score for each domain. The RNN block was trained using an identified set of positive vectors, which represents known BGCs, and a synthesized set of negative vectors, which is unlikely to represent BGCs. Candidate BGCs are selected by averaging BGC class scores across genes within a domain and comparing the average BGC class scores to a threshold. The candidate BGCs are provided for display on a user interface.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: June 11, 2024
    Assignees: Merck Sharp & Dohme LLC, MSD Czech Republic s.r.o.
    Inventors: Geoffrey D. Hannigan, David Prihoda, Jindrich Soukup, Christopher Harron Woelk, Danny A. Bitton
  • HIV drug combination for increasing barrier against resistance
    Patent number: 12005072
    Abstract: The instant invention relates to a method for reducing the risk for development of anti-viral treatment resistance due to an HIV mutation in a human subject infected with HIV, comprising administering EFdA in combination with one or more anti-viral agents.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: June 11, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Daria Jean Hazuda, Ming-Tain Lai
  • NOVEL FORMS OF CYCLIC DINUCLEOTIDE COMPOUNDS
    Publication number: 20240182511
    Abstract: Novel forms of 2-amino-9-[(2R,5R,7R,8S,10R,12aR,14R,15S,15aR,16R)-14-(6-amino-9H-purin-9)-yl)-15,16-difluoro-2,10-dihydroxy-2,10-disulfidooctahydro-12H-5.8-methanofuro[3,2-1][1,3,6,9,11,2,10]pentaoxa-diphosphacyclotetradecin-7-yl]-1,9-dihydro-6H-purin-6-one, which include crystalline salts and hydrates of 2-amino-9)-[(2R,5R,7R,8,S,10R,12aR,14R,15S,15aR,16R)-14-(6-amino-9H-purin-9-yl)-15,16-difluoro-2,10-dihydroxy-2,10-disulfido-octahydro-12H-5,8-methanofuro[3,2-1][1,3,6,9,11,2,10]pentaoxa-diphosphacyclotetradecin-7-yl]-1,9-dihydro-6H-purin-6-one, may be useful as inductors of type I interferon production, specifically as STING active agents.
    Type: Application
    Filed: April 4, 2022
    Publication date: June 6, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Stephanus Axnanda, Zachary E. Dance, David J. Lamberto, Zhijian Liu, Feng Peng, Marc Poirier, Matthew S. Winston
  • STABLE FORMULATIONS OF ANTI-TIGIT ANTIBODIES ALONE AND IN COMBINATION WITH PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20240182573
    Abstract: The present invention relates to stable formulations of antibodies against T cell immunoreceptor with Ig and ITIM domains (TIGIT), optionally further containing an anti-human programmed death receptor 1 (PD-1) antibody or antigen binding fragment thereof. Also provided are methods of treating various cancers and chronic infections with the formulations of the invention.
    Type: Application
    Filed: January 25, 2024
    Publication date: June 6, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Arnab De, Chakravarthy Nachu Narasimhan
  • POLYPEPTIDES BINDING ADAMTS5, MMP13 AND AGGRECAN
    Publication number: 20240181006
    Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).
    Type: Application
    Filed: October 6, 2023
    Publication date: June 6, 2024
    Applicants: Merck Patent GmbH, ABLYNX NV
    Inventors: Soren STEFFENSEN, Gerald BESTE, Hans GUEHRING, Lars TOLEIKIS, Christoph LADEL, Sven LINDEMANN, Roland KELLNER, Ralf GUENTHER
  • Laser additive and its use in polymer materials
    Patent number: 11999858
    Abstract: The present invention relates to pigments which comprise niobium-doped titanium dioxide as well as a layer encapsulating the niobium-doped titanium dioxide, to polymer materials containing same and to the use of said pigments as laser absorbing additive in products comprising at least one polymer material and said encapsulated niobium-doped titanium dioxide containing pigments.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: June 4, 2024
    Assignee: MERCK PATENT GMBH
    Inventor: Koshiro Kunii
  • Dielectric copolymer materials
    Patent number: 11999893
    Abstract: A polymerizable mixture which can be used to form a dielectric material for the preparation of passivation layers in electronic devices comprises a first monomer and a second monomer which may react to form a copolymer providing excellent film forming capability, excellent thermal properties, and excellent mechanical properties. The polymerizable mixture can be used in a method for forming copolymers and the copolymers can be used in an electronic device as dielectric material. The copolymers can also be used in a manufacturing method for preparing a packaged microelectronic structure and microelectronic devices comprising the packaged microelectronic structure.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: June 4, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Gregor Larbig, Pawel Miskiewicz
  • Polycarbosilazane, and composition comprising the same, and method for producing silicon-containing film using the same
    Patent number: 11999827
    Abstract: [Problem] To provide a polycarbosilazane making it possible to form a silicon-containing film which is bearable to acid etching, and a composition comprising the polycarbosilazane. [Means for Solution] The present invention provides a polycarbosilazane comprising a repeating unit of —[R1R2Si—(CH2)n]— and —(R3R4Si—NR5)—, wherein R1, R2, R3 and R4 are each independently a single bond, hydrogen or C1-4 alkyl; R5 is independently a single bond or hydrogen; and n is 1-2, and a composition comprising the polycarbosilazane. The present invention also provides a method for forming a silicon-containing film, comprising coating the composition above a substrate and heating.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: June 4, 2024
    Assignee: Merck Patent GmbH
    Inventors: Toshiya Okamura, Tetsuo Okayasu, Thorsten Vom Stein
  • Formulation containing a highly branched polymer, highly branched polymer and electro-optical device containing this highly branched polymer
    Patent number: 11999819
    Abstract: The present invention relates to formulations comprising at least one hyper-branched polymer which contains 30 to 70 mol % of at least one hole-transporting recurring unit A, 5 to 30 mol % of least one branching recurring unit B, 5 to 30 mol % of at least one further recurring unit C and 5 to 40 mol % of least one end group E, where the recurring units A, B and C are different from one another, and at least one organic solvent, characterised in that the formulation has a viscosity of ?25 mPas. The present invention furthermore relates to the corresponding hyperbranched polymers and to processes for the preparation thereof. The present invention additionally also relates to the use of the hyperbranched polymers according to the invention in electronic or opto-electronic devices, and to electronic or opto-electronic devices containing these polymers.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: June 4, 2024
    Assignee: Merck Patent GmbH
    Inventors: Beate Burkhart, Miriam Engel, Matthias Hengst, Holger Heil, Manuel Hamburger, Christoph Leonhard, Gaelle Bealle
  • Liquid-crystal medium comprising polymerisable compounds and the use thereof in liquid-crystal displays
    Patent number: 11999891
    Abstract: The present invention relates to a liquid-crystal (LC) medium comprising one or more polymerisable compounds and to the use of the LC medium for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the polymer sustained alignment (PS, PSA) or self-aligning (SA) type.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: June 4, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Helmut Haensel, Qiong Tong, Edward Plummer, Rocco Fortte, Thomas Eichhorn
  • Meta-learning for cardiac MRI segmentation
    Patent number: 12002202
    Abstract: Methods and systems are described for image segmentation. A machine learning model is applied to a set of images to generate results. The results may be obtained as a probability map for each image in the set of images. The model may be trained by accessing a set of labeled images, each image associated with a label indicating a location of a feature within a respective image. An initial set of parameters is accessed. An encoder is initialized with the initial set of parameters. The encoder is applied to the set of labeled images to generate a prediction of a feature location within each image. The initial set of parameters are updated based on the predictions and the label associated with the labeled images. The updated set of parameters and an additional set of parameters generated using a set of unlabeled images are aggregated.
    Type: Grant
    Filed: August 9, 2021
    Date of Patent: June 4, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Dani Kiyasseh, Antong Chen, Albert Joseph Swiston, Jr., Ronghua Chen
  • DIELECTRIC MATERIALS BASED ON AMIDE-IMIDE-EXTENDED BISMALEIMIDES
    Publication number: 20240174805
    Abstract: The present invention relates to a new class of dielectric polymer material, which is particularly suitable for the manufacturing of electronic devices. The dielectric polymer material is formed by reacting bismaleimide compounds and shows an advantageous well-balanced profile of favorable material properties. The bismaleimide compounds have an oligomeric structure with an amide-imide extended repeating unit in the middle part of the molecule and maleimide groups at each terminal end of the molecule. There is further provided a method for forming said dielectric polymer material. Beyond that, the present invention relates to the dielectric polymer material and to an electronic device comprising the same.
    Type: Application
    Filed: March 1, 2022
    Publication date: May 30, 2024
    Applicant: MERCK PATENT GMBH
    Inventors: Gregor LARBIG, Frank Egon MEYER, Pawel MISKIEWICZ
  • HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
    Publication number: 20240174679
    Abstract: The present invention is directed to certain (hetero)aroyl 4-aminopyrazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, R1, R2, and R3 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Application
    Filed: March 14, 2022
    Publication date: May 30, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Kaleen Konrad Childers, J. Michael Ellis, Peter J. Fuller, Hakan Gunaydin, Jack D. Scott, Haiqun Tang, Charles S. Yeung